Table 1.

Patient characteristics (primary phase)

CharacteristicsHormone resistant (n = 27)Triple negative (n = 13)
Age, years
 Median5547
 Range(35–70)(31–67)
Race
 White21 (78%)10 (77%)
 Black3 (11%)3 (23%)
 Other3 (11%)0 (0%)
ECOG performance status
 011 (41.5%)7 (54%)
 115 (55%)6 (46%)
 21 (0.5%)0 (0%)
Disease status
 Locally advanced1 (0.5%)1 (0.7%)
 Metastatic26 (95.5%)12 (93.3%)
Location of disease
 Visceral24 (89%)10 (77%)
 Nonvisceral3 (11%)3 (23%)
Median number of prior therapies (all settings; range)
 Hormonal3 (1–5)0 (0–1)
 Cytotoxic3 (1–10)3 (1–6)
Median no. of regimens for metastatic disease (range)
 Hormonal2 (0–4)0 (0–1)
 Cytotoxic2 (0–9)2 (0–4)
Optional continuation phase12 (44%)4 (31%)
Event monitoring15 (56%)9 (69%)
  • Abbreviation: ECOG, Eastern Cooperative Oncology Group.